LONDON (Alliance News) - GlaxoSmithKline PLC said Friday a late stage study of its drug eltrombopag for the treatment of chronic immune thrombocytopenia in paediatric patients had met its primary endpoint.
Immune thrombocytopenia is a bleeding disorder where the blood does not clot properly.
The drug, which its marketed as Promacta in the US and Revolade in Europe, showed a statistically significant improvement in platelet counts compared to a placebo.
GlaxoSmithKline said that the results were important, as the children involved in the study had failed other standard therapies.
"We look forward to continuing to assess the potential of eltrombopag in these patients and to moving forward with planned regulatory submissions for a paediatric indication in chronic immune thrombocytopenia later this year," said Head of Oncology Research and Development Rafael Amado in a statement.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)